Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 30 October 2018, 10:10 HKT/SGT
Share:
    

Source: NEC Corporation
NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene's myvac Platform

TOKYO, Oct 30, 2018 - (JCN Newswire) - NEC Corporation (TSE: 6701) and Transgene today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration aimed at the treatment of solid cancers. The companies will cooperate in clinically assessing the predictive capabilities of NEC's artificial intelligence (AI) and the therapeutic potential of Transgene's myvac(1) MVA-based viral vector platform in an individualized immunotherapy for the treatment of solid cancers. The experimental products from this collaboration are expected to enter clinical trials in 2019.

NEC and Transgene will co-invest in the first stage of development of an individualized immunotherapy, which includes clinical trials focusing on ovarian cancer and HPV-negative head and neck cancer.

Immunotherapy is rapidly becoming the treatment of choice to fight cancer as it activates the patient's own immune system to attack cancer cells.

NEC and Transgene have capitalized on the recent progress in AI and advances in genome sequencing to create individualized immunotherapy, which is adapted to the unique characteristics of each patient's mutational landscape as well as their predicted immune responses. The product is based on a viral vector (MVA) developed by Transgene with a proven clinical safety track record and is known for its efficient immunogenicity and anti-tumor efficacy in patients.

The viral vector will be used to target neoantigens identified using NEC's proprietary algorithm. NEC has been developing solutions in the drug discovery field for close to two decades. NEC's neoantigen prediction system(2) was developed and validated based on publicly available databases, as well as internal wet lab datasets, some of which were already used to identify clinically relevant antigens in other oncology indications.

These planned clinical trials leverage the world-leading expertise and technologies of a network of companies and research centers, including:

NEC's cutting-edge AI technology, "NEC the WISE"(3), for identifying and prioritizing patient-specific neoantigens, and Transgene's unrivaled MVA-based, viral vector technology and the myvac platform.

"The emerging personalized medicine field holds great potential for the application of NEC's core technology, and we are pleased to be working with Transgene with the goal of developing state-of-the-art personalized immunotherapies," said Motoo Nishihara, Senior Vice President, Head of NEC Laboratories.

"Engaging the body's own immune system in the fight against cancer has shown great promise and sparked unprecedented interest among oncology drug makers. This makes it imperative for NEC to become part of the immunotherapy race as soon as possible," said Osamu Fujikawa, Senior Vice President, Business Innovation Unit, NEC Corporation.

"This collaboration brings together artificial intelligence and our expertise in viral vector engineering to enable the development of a truly innovative treatment based on the myvac platform. We believe that our collaboration with NEC will allow us to provide an efficacious and robust therapy for the many patients who have solid tumors and could benefit from this cutting-edge individualized approach, and to successfully advance the development of the myvac platform to the market" said Eric Quemeneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene.

(1) myvac
myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. The myvac-derived products are designed to stimulate the patient's immune system, recognize and destroy tumors using the patient's own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities.
(2) NEC's Neoantigen Prediction System
NEC's neoantigen prediction utilizes its proprietary AI, such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets. NEC comprehensively evaluates the candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.
(3) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.
Press release:
NEC announces new AI technology brand, "NEC the WISE"
https://www.nec.com/en/press/201607/global_20160719_01.html
NEC's AI Research:
https://www.nec.com/en/global/rd/crl/ai/index.html


About NEC Corporation

NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security efficiency and fairness of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at https://www.nec.com.

Contact:
NEC
Seiichiro Toda        
s-toda@cj.jp.nec.com
+81-3-3798-6511


Oct 30, 2018 10:10 HKT/SGT
Source: NEC Corporation

NEC Corporation (TSE: 6701)

Topic: Press release summary
Sectors: Enterprise IT, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Multimedia
(from left: Eric Quemeneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer, Transgene; Kaidre Bendjama, Transgene; Motoo Nishihara, Senior Vice President, Head of NEC Laboratories; Osamu Fujikawa, Senior Vice President, Business Innovation Unit, NEC Corporation)
View Image
 
NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation
Nov 12, 2018 10:49 HKT/SGT
NEC's Greenhouse Gas Reduction Targets Approved by the Science Based Targets Initiative
Nov 8, 2018 18:48 HKT/SGT
NEC Takes Passenger Experiences to New Heights at the Future Travel Experience Asia Expo 2018
Nov 7, 2018 11:39 HKT/SGT
NEC to Provide Facial Recognition at Airport Customs
Nov 6, 2018 15:26 HKT/SGT
NEC Technology Automatically Identifies Cyberattack Risks for ICT Systems and Important Infrastructure
Nov 5, 2018 09:19 HKT/SGT
NEC Collaborates with A10 Networks in the Network Security Area
Nov 2, 2018 14:00 HKT/SGT
"Think Global, Think Hong Kong" Concludes in Tokyo
Nov 2, 2018 10:56 HKT/SGT
NEC Showcases Biometrics and Blockchain Technologies for the Financial Sector at the Singapore FinTech Festival 2018
Nov 1, 2018 17:05 HKT/SGT
NEC Expands Broadband Availability in Sweden with the iPASOLINK EX-Advanced Radio
Oct 26, 2018 10:26 HKT/SGT
AI Acceleration with NEC's New Vector Computer
Oct 25, 2018 13:08 HKT/SGT
NEC Releases "Wireless Transport Modernization for 5G" White Paper
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: